67515-76-8

Basic information

• Product Name: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)
• Synonyms: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI);Methyl 5-amino-pyridine-2-carboxylate;Methyl 5-amino-pyridine-2...;METHYL 5-AMINOPICOLINATE;2-Pyridinecarboxylic acid, 5-aMino-, Methyl ester;Methyl 5-amino-2-pyridinecarboxylate;5-Amino-2-(carbomethoxy)pyridine
• CAS NO: 67515-76-8
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.15
• Product Categories: GLYCINESCAFFOLD;CARBOXYLICESTER;Heterocycle-Pyridine series
• Mol File: 67515-76-8.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 333.651 °C at 760 mmHg
• Flash Point: 155.587 °C
• Appearance: /
• Density: 1.239 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.63±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(67515-76-8)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(67515-76-8)

Safety Data

• Hazardous Substances Data: 67515-76-8(Hazardous Substances Data)

Usage

Uses

Methyl 5-Aminopyridine-2-Carboxylate is used in preparation of N-Hydroxypyridine-2-carboxamide, N-Hydroxypyridazine-3-carboxamide, and N-Hydroxypyrimidine-2-carboxamide derivatives as Dihydroceramide desaturase-1 inhibitors.

InChI:InChI=1/C7H8N2O2/c1-11-7(10)6-3-2-5(8)4-9-6/h2-4H,8H2,1H3

Upstream product

• 30651-24-2 5-nitropicolinic acid 
• 4548-45-2 2-chloro-5-nitropyridine 
• 60891-70-5 1,3-diethyl 2-(5-nitropyridin-2-yl)propanedioate 
• 55338-73-3 5-amino-2-cyanopyridine 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 67-56-1 methanol 
• 29682-14-2 5-nitro-pyridine-2-carboxylic acid methyl ester 

Downstream Products

• 67515-84-8 5-(3-fluoro-benzylideneamino)-pyridine-2-carboxylic acid methyl ester 
• 153685-22-4 Methyl 5-[(4-fluorophenylsulfonyl)amino]-pyridine-2-carboxylate 
• 131052-40-9 methyl 5-[N-(tert-butoxycarbonyl)amino]-pyridine-2-carboxylate 
• 872355-63-0 methyl 1H-pyrrolo[3,2-b]pyridine-5-carboxylate 
• 872355-64-1 1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid 
• 107504-07-4 5-fluoro-pyridine-2-carboxylic acid methyl ester 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Targeting breast cancer stem cells by novel HDAC3-selective inhibitors

Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity. Pursuant to our previous finding that HDAC8 regulates CSCs in triple-negative breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway. Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28. These two derivatives exhibited high potency and isoform selectivity in HDAC3 inhibition. Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the downregulation of β-catenin.